NEW YORK (TheStreet) -- CHANGE IN RATINGS
Cubist Pharmaceuticals (CBST) rated new Buy at Goldman. Stock also placed on the Conviction List. $54 price target. CXA will likely be the company's next big growth driver.
CVS Caremark (CVS) upgraded at BMO from Market Perform to Outperform, BMO Capital said. $53 price target. Company should see improved margins and earnings power in the coming quarters.
Dril-Quip (DRQ) downgraded at BofA/Merrill from Buy to Underperform, Bank of America/Merrill Lynch said. Valuation call, based on a $79 price target.FirstEnergy (FE) downgraded at UBS to Neutral from Buy, UBS said. $49 price target. Standing aside on opaque outlook. First Energy downgraded at BMO from Outperform to Market Perform, BMO Capital said. $48 price target. Management has limited earnings visibility. Fossil (FOSL) downgraded at Citigroup to Neutral from Buy, Citigroup said. $100 price target. Valuation call after rally on quarterly results. Groupon (GRPN) downgraded at Sterne Agee from Buy to Neutral, Sterne Agee said. Estimates also cut, as growth appears to be slowing. Halliburton (HAL) upgraded to buy at TheStreet Ratings. Jive Software (JIVE) downgraded at Citigroup to Neutral from Buy, Citigroup said. $21 price target. Thesis not playing out as fast as we'd hoped. Jack Henry (JKHY) upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Company has a strong balance sheet and the spending environment is improving. MGE Energy (MGEE) upgraded at DA Davidson from Underperform to Neutral, DA Davidson said. Valuation call, based on a $48.50 price target. MGM (MGM) downgraded to sell at TheStreet Ratings. VeriFone (PAY) downgraded at UBS to Neutral from Buy, UBS said. $41 price target. Catalysts played out. Par Pharmaceutical (PRX) downgrade at UBS to Neutral from Buy, UBS said. $58 price target. Valuation call given current TPG offer price. Rackspace (RAX) upgraded at Pacific Crest to Outperform, Pacific Crest said. $62 price target. Company is realizing higher margins. Sapient (SAPE) downgraded at Wells from Outperform to Market Perform, Wells Fargo said. Company is seeing slower growth in its Nitro segment. Vectren (VVC) rated new Buy at Brean. $36 price target. Company has a solid yield and can deliver consistent growth over the long term.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV